Department of Haematology, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Int J Mol Sci. 2023 May 31;24(11):9592. doi: 10.3390/ijms24119592.
Survival in patients with hematological malignancies has improved over the years, both due to major developments in anticancer treatment, as well as in supportive care. Nevertheless, important and debilitating complications of intensive treatment regimens still frequently occur, including mucositis, fever and bloodstream infections. Exploring potential interacting mechanisms and directed therapies to counteract mucosal barrier injury is of the utmost importance if we are to continue to improve care for this increasingly growing patient population. In this perspective, I highlight recent advances in our understanding of the relation of mucositis and infection.
近年来，由于癌症治疗的重大进展以及支持性护理的改善，血液系统恶性肿瘤患者的生存率得到了提高。然而，强化治疗方案仍会频繁导致严重且使人虚弱的并发症，包括黏膜炎、发热和血流感染。如果我们要继续为这个日益增长的患者群体提供更好的护理，探索潜在的相互作用机制和靶向治疗以对抗黏膜屏障损伤至关重要。在这篇观点文章中，我强调了我们对黏膜炎和感染关系的理解的最新进展。
